Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKOHC5)

Drug Name

Astegolimab Drug Info

Synonyms

RG6149; MSTT1041A

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 3	[1]
Asthma	CA23	Phase 2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-1 receptor-like 1 (IL1RL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK3772847	DM7J41B	Asthma	CA23	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-1 receptor-like 1 (IL1RL1)	TT4GZA4	ILRL1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05878769) A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT02918019) A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma. U.S.National Institutes of Health.
3	Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022 May;10(5):469-477.
4	Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PLoS One. 2023 Feb 3;18(2):e0281205.